COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04798027

Sanofi Pasteur

Contact-US@sanofi.com

2021-03-15

Terminated

RCT

Randomized

Parallel

Blind label

multi-center

Prevention

inclusion criteria: aged >= 18 years on the day of inclusion. a female participant was eligible to participate if she was not pregnant or breastfeeding and one of the following conditions applies: was of non-childbearing potential. to be considered of non-childbearing potential, a female must be pre-menarche or post-menopausal for at least 1 year, or surgically sterile. or was of childbearing potential and agreed to use an effective contraceptive method or abstinence from at least 4 weeks prior to the first vaccination until at least 12 weeks after the last vaccination. a participant of childbearing potential must had a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 8 hours before the study intervention. informed consent form had been signed and dated. participant not eligible to receive, based on local guidance, or if eligible does not intend to receive an authorized/approved covid-19 vaccine from first vaccination until completion of the key timepoint of day 43 of follow-up of this study.

history of covid-19 disease or prior severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection confirmed serologically. known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months). chronic illness or condition considered to potentially increase the risk for severe covid illness or that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion. known liver disease or fatty liver. positive test for chronic active hepatitis b surface antigen, hepatitis b core antibody, hepatitis c antibody, or human immunodeficiency virus (hiv) antibody from blood work collected at screening visit. bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination based on investigator's judgment. receipt of immuneglobulins, blood or blood-derived products in the past 3 months. prior administration of a coronavirus vaccine (sars-cov-2, sars-cov, middle east respiratory syndrome coronavirus [mers-cov]). receipt of any vaccine in the 30 days preceding the first study vaccination or planned receipt of any vaccine in the 30 days following the last study vaccination except for influenza vaccination, which may be received at least 2 weeks before and a minimum of 2 weeks after study vaccines. receipt of any therapy known to have in-vitro antiviral activity against sars-cov-2 within 72 hours prior to the first blood draw or planned use of such therapy 72 hours prior to study immunogenicity blood draws at day 22 and day 36. residence in a nursing home or long-term care facility. health care workers providing direct patient care for covid-19 participants. the above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

7

Sanofi Pasteur, a Sanofi Company

18

100

Australia;Brazil;Honduras;United States

Healthy volunteers

N/A

182

2-fold and 4-fold rise in neutralizing antibody titer;Fold-rise in neutralizing antibody titer;Neutralizing antibody titer;Occurrence of neutralizing antibody seroconversion;Presence of immediate adverse events;Presence of medically attended adverse events;Presence of out-of-range biological test results;Presence of serious adverse events (SAE) and adverse events of special interest (AESI);Presence of solicited injection site reactions and systemic reactions;Presence of unsolicited adverse events

None

Phase 1/Phase 2

[{"arm_notes": "1", "treatment_id": 1928, "treatment_name": "Mrt5500", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "1", "treatment_id": 1928, "treatment_name": "Mrt5500", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "1", "treatment_id": 1928, "treatment_name": "Mrt5500", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "2;days1-22", "treatment_id": 1928, "treatment_name": "Mrt5500", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "2;days1-22", "treatment_id": 1928, "treatment_name": "Mrt5500", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "2;days1-22", "treatment_id": 1928, "treatment_name": "Mrt5500", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]